EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Examining Heterogeneity of Patient Outcomes in a Randomized Controlled Trial for Binge‐Eating Disorder Testing Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined

Sydney Yurkow iD, William P Bowman iD, Valentina Ivezaj iD, Carlos M Grilo iD

International Journal of Eating Disorders · 2026-08 · 59 (8) · 1838-1846

DOI: 10.1002/eat.70115 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Eating Disorders, online erschienen am 29.04.2026. Verfasst von Sydney Yurkow und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Lisdexamfetamine Dimesylate, Binge-Eating Disorder. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Although trials have documented the overall effectiveness of cognitive‐behavioral therapy (CBT) and lisdexamfetamine (LDX) for binge‐eating disorder (BED), the nature and extent of individual patient variability in outcomes have not been examined. This secondary analysis of a controlled trial examined heterogeneity of outcomes with CBT and LDX, alone and combined, for BED.

Methods

One hundred and forty‐one patients with BED with co‐occurring obesity were randomized to CBT, LDX, or combined CBT+LDX 3‐month treatments. Changes in binge‐eating frequency, eating‐disorder psychopathology, weight, and depression were repeatedly assessed. Outcomes were dichotomized as increased or decreased/no change, and differences between treatments were explored. Corset plots were used to examine changes in outcomes at the patient level.

Results

In CBT, 94.4% ( N = 34) patients reported decreased binge‐eating frequency and 75.0% ( N = 24) decreased eating‐disorder psychopathology. In LDX, 90.5% ( N = 38) reported decreased binge‐eating frequency and 89.7% ( N = 35) decreased eating‐disorder psychopathology. In CBT+LDX, 100% ( N = 44) reported improvements in binge eating and eating‐disorder psychopathology. Patients not prescribed LDX had significantly fewer decreases in weight: in CBT, 55.6% ( N = 20) had weight loss, compared to 92.9% ( N = 39) in LDX and 81.3% ( N = 4) in CBT+LDX. No differences in decreased depression scores were observed across treatments (80.0% ( N = 28) in CBT; 89.2% ( N = 33) in LDX; 86.1% ( N = 38) in CBT+LDX).

Conclusion

Frequency of individual cases with increases in binge‐eating, eating‐disorder psychopathology, and depression were low in CBT and LDX treatments, and particularly so for the combined CBT+LDX approach. These participant‐level findings add important clinical context regarding the significant overall improvements associated with CBT, LDX, and CBT+LDX for BED. Trial Registration: Clinicaltrials.gov registration: NCT03924193 (Cognitive‐Behavioral and Pharmacologic (LDX) Treatment of Binge‐Eating Disorder and Obesity: Acute Treatment)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive Behavioral TherapyLisdexamfetamine DimesylateBinge-Eating DisorderHumansFemaleAdultMaleTreatment Effect HeterogeneityCombined Modality TherapyMiddle AgedTreatment OutcomeObesity

Stichwörter der Autor:innen

binge‐eating disordercognitive behavioral therapyeating disorderlisdexamfetamineobesity

Substanzen

Lisdexamfetamine Dimesylate

Autor:innen und Institutionen

  • Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Astronomy Department, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Sydney Yurkow, William P Bowman, Valentina Ivezaj, Carlos M Grilo

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Yurkow, S., Bowman, W. P., Ivezaj, V., & Grilo, C. M. (2026). Examining Heterogeneity of Patient Outcomes in a Randomized Controlled Trial for Binge‐Eating Disorder Testing Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined. International Journal of Eating Disorders, 59(8), 1838-1846. https://doi.org/10.1002/eat.70115

Vancouver

Yurkow S, Bowman WP, Ivezaj V, Grilo CM. Examining Heterogeneity of Patient Outcomes in a Randomized Controlled Trial for Binge‐Eating Disorder Testing Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined. International Journal of Eating Disorders. 2026;59(8):1838-1846. doi:10.1002/eat.70115

BibTeX
@article{Yurkow2026,
  author = {Yurkow, Sydney and Bowman, William P and Ivezaj, Valentina and Grilo, Carlos M},
  title = {Examining Heterogeneity of Patient Outcomes in a Randomized Controlled Trial for Binge‐Eating Disorder Testing Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined},
  journal = {International Journal of Eating Disorders},
  year = {2026},
  volume = {59},
  number = {8},
  pages = {1838--1846},
  doi = {10.1002/eat.70115}
}
Kostenlos starten →